Halozyme Therapeutics Inc. (NASDAQ:HALO)’s traded shares stood at 1.93 million during the latest session, with the company’s beta value hitting 1.27. At the last check today, the stock’s price was $38.69, to imply a decrease of -3.40% or -$1.36 in intraday trading. The HALO share’s 52-week high remains $59.46, putting it -53.68% down since that peak but still an impressive 10.29% since price per share fell to its 52-week low of $34.71. The company has a valuation of $5.57B, with an average of 1.61 million shares in intraday trading volume over the past 10 days and average of 1.26 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Halozyme Therapeutics Inc. (HALO), translating to a mean rating of 2.30. Of 10 analyst(s) looking at the stock, 1 analyst(s) give HALO a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.47.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Halozyme Therapeutics Inc. (NASDAQ:HALO) trade information
After registering a -3.40% downside in the latest session, Halozyme Therapeutics Inc. (HALO) has traded red over the past five days. The stock hit a weekly high of 43.67 this Wednesday, 03/15/23, dropping -3.40% in its intraday price action. The 5-day price performance for the stock is -9.48%, and -20.73% over 30 days. With these gigs, the year-to-date price performance is -32.00%. Short interest in Halozyme Therapeutics Inc. (NASDAQ:HALO) saw shorts transact 7.01 million shares and set a 5.05 days time to cover.
Analysts on Wall Street suggest a consensus price target of $52.89, implying an increase of 26.85% to the stock’s recent value. The extremes give us $26.00 and $68.00 for target low and target high price respectively. As such, HALO has been trading -75.76% off suggested target high and 32.8% from its likely low.
Halozyme Therapeutics Inc. (HALO) estimates and forecasts
Looking at statistics comparing Halozyme Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Halozyme Therapeutics Inc. (HALO) shares are -8.99% down over the last 6 months, with its year-to-date growth rate higher than industry average at 23.08% against 9.40%. Revenue is forecast to grow 11.90% this quarter before jumping 31.90% for the next one. The rating firms project that company’s revenue will grow 51.50% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is $192.05 million. Meanwhile, for the quarter ending Mar 2023, a total of 5 analyst(s) estimate revenue growth to $195.59 million.Earnings reports from the last fiscal year show that sales brought in $102 million and $117.28 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 88.30% before jumping 66.80% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 26.00% for the past 5-year period. While 2023 is set for a -47.60% return in earnings, projections for the next 5 years are at 30.00% annually.
Halozyme Therapeutics Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Halozyme Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Halozyme Therapeutics Inc. (NASDAQ:HALO)’s Major holders
Halozyme Therapeutics Inc. insiders hold 1.09% of total outstanding shares, with institutional holders owning 99.36% of the shares at 100.45% float percentage. In total, 99.36% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 18.2 million shares (or 13.46% of shares), all amounting to roughly $719.61 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 13.34 million shares, or about 9.86% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $527.27 million.
We also have iShares Core S&P Midcap ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Halozyme Therapeutics Inc. (HALO) shares. Going by data provided on Dec 30, 2022, iShares Core S&P Midcap ETF holds roughly 4.17 million shares. This is just over 3.09% of the total shares, with a market valuation of $237.5 million. Data from the same date shows that the other fund manager holds a little less at 4.12 million, or 3.05% of the shares, all valued at about 162.91 million.